Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection

Chronic HBV infection (CHB) is a major contributor to liver-related deaths worldwide. The ultimate endpoint of CHB treatment is sustained HBV surface antigen (HBsAg) loss.

Here, we report the design of a series of HBV surface antigen inhibitors which promotes reduction of HBV antigens in vitro and in vivo.

https://pubmed.ncbi.nlm.nih.gov/36089112/

View Now
← Return to Resources

Related Content

The Son of Sevenless (SOS) protein is a guanine nucleotide exchange factor that acts as a key activator for KRAS...

VIEW RESOURCE

The RAS family of small GTPases are among the most frequently mutated oncogenes in human cancer. Previously viewed as undruggable,...

VIEW RESOURCE
← View all Biochemical Assays Resources
× peptide, amino acid

Contact An Expert Today!